A Phase I, Open-Label, Parallel Group Study To Evaluate ACH-0144471 Safety, Tolerability, And Pharmacokinetics In Subjects With Normal Renal Function And Subjects With Renal Dysfunction
Latest Information Update: 06 Nov 2023
At a glance
- Drugs Danicopan (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions
- Sponsors Alexion Pharmaceuticals
- 28 Jun 2021 New trial record